A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

ClinicalTrials.gov ID: NCT05669430

Public ClinicalTrials.gov record NCT05669430. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies

Study identification

NCT ID: NCT05669430
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: GV20 Therapeutics; Industry
Enrollment: 365 participants

Conditions and interventions

Conditions

Interventions

GV20-0251 Biological
GV20-0251 and Pembrolizumab [KEYTRUDA®] Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 22, 2023
Primary completion: Dec 14, 2026
Completion: Sep 4, 2027
Last update posted: Feb 12, 2025

2023 – 2027

United States locations

U.S. sites: 13
U.S. states: 12
U.S. cities: 12

Facility	City	State	ZIP	Site status
The Angeles Clinic and Research Institute	Los Angeles	California	90025	Recruiting
HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE	Denver	Colorado	80218	Not yet recruiting
Yale University	New Haven	Connecticut	06511	Recruiting
Florida Cancer Specialists & Research Institute, LLC	Fort Myers	Florida	33916	Not yet recruiting
Community Health Network, Inc.	Indianapolis	Indiana	46256	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center	Detroit	Michigan	48201	Recruiting
NYU Langone Health	New York	New York	10016	Recruiting
Oregon Health & Science University	Portland	Oregon	97239	Recruiting
Verdi Oncology Tennessee, Scri Oncology Partners	Nashville	Tennessee	37203	Not yet recruiting
Oncology Consultants, P.A.	Houston	Texas	77030	Recruiting
The University of Texas M. D. Anderson Cancer Center	Houston	Texas	77030	Recruiting
Virginia Cancer Specialists	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05669430, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 12, 2025 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05669430 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →